Editorial: metformin for portal hypertension-old dog, new tricks?

Naaventhan Palaniyappan^{1

2}, Jonathan A Fallowfield³

Affiliations

¹ NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust, University of Nottingham, Nottingham, UK.
² School of Medicine, University of Nottingham, Nottingham, UK.
³ Centre for Inflammation Research, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK.

Editorial

Naaventhan Palaniyappan et al. Aliment Pharmacol Ther. 2021 Aug.

. 2021 Aug;54(3):345-346.

doi: 10.1111/apt.16484.

Naaventhan Palaniyappan^{1

2}, Jonathan A Fallowfield³

¹ NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust, University of Nottingham, Nottingham, UK.
² School of Medicine, University of Nottingham, Nottingham, UK.
³ Centre for Inflammation Research, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK.

No abstract available

Comment in

Editorial: metformin for portal hypertension-old dog, new tricks? Authors' reply.
Rittig N, Aagaard NK, Villadsen GE, Sandahl TD, Jessen N, Grønbaek H, George J. Rittig N, et al. Aliment Pharmacol Ther. 2021 Aug;54(3):347. doi: 10.1111/apt.16503. Aliment Pharmacol Ther. 2021. PMID: 34236099 No abstract available.

Randomised clinical study: acute effects of metformin versus placebo on portal pressure in patients with cirrhosis and portal hypertension.
Rittig N, Aagaard NK, Villadsen GE, Sandahl TD, Jessen N, Grønbaek H, George J. Rittig N, et al. Aliment Pharmacol Ther. 2021 Aug;54(3):320-328. doi: 10.1111/apt.16460. Epub 2021 Jun 24. Aliment Pharmacol Ther. 2021. PMID: 34165199 Clinical Trial.

1. Garcia-Pagan JC, Gracia-Sancho J, Bosch J. Functional aspects on the pathophysiology of portal hypertension in cirrhosis. J Hepatol. 2012;57:458-461.
1. Rodrigues SG, Mendoza YP, Bosch J. Beta-blockers in cirrhosis: evidence-based indications and limitations. J Hep Rep. 2020;2:100063.
1. Abraldes JG, Albillos A, Banares R, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology. 2009;136:1651-1658.
1. Kreisel W, Deibert P, Kupcinskas L, et al. The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-study. Dig Liver Dis. 2015;47:144-150.
1. Gifford FJ, Dunne PDJ, Weir G, et al. A phase 2 randomised controlled trial of serelaxin to lower portal pressure in cirrhosis (STOPP). Trials. 2020;21:260.